Bone Biologics Inc.
This article was originally published in Start Up
Executive SummaryBone Biologics' protein for stimulating bone growth was originally isolated from areas of active bone growth in humans. Based on animal studies to date, the company's founders claim that its UCB-1, performs as well if not better than marketed BMPs because of its molecular specificity. The company plans to combine UCB-1 with a proprietary scaffold to create biological solutions to a number of bone disorders.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.